[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"The First Affiliated Hospital of Anhui Medical University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":284},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,50,77,98,125,150,179,207,233,257],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100053367","phase-4-ai-assisted-lifestyle-intervention-versus-tirzepatide-for-obesity-and-newly-diagnosed-type-2-diabetes-100053367",false,"NCT07697391","AI-Assisted Lifestyle Intervention Versus Tirzepatide for Obesity and Newly Diagnosed Type 2 Diabetes","A Multicenter Randomized Controlled Trial Evaluating AI-Assisted Intensive Lifestyle Intervention Versus Tirzepatide for Glycemic and Weight Management in Patients With Obesity and Newly Diagnosed Type 2 Diabetes","AI-LIFE-T2D-OB","Inclusion Criteria:\n\n1. Male or female participants aged 18 to 65 years.\n2. Newly diagnosed type 2 diabetes mellitus, defined as diagnosis within 3 years and no use of glucose-lowering medications within the past 3 months. Diagnosis should meet the 1999 World Health Organization criteria, including at least one of the following: random plasma glucose ≥11.1 mmol\u002FL, fasting blood glucose ≥7.0 mmol\u002FL, 2-hour postprandial blood glucose ≥11.1 mmol\u002FL, or HbA1c ≥6.5% and ≤10.0%. Participants without typical diabetes symptoms should have repeat testing for confirmation.\n3. Body mass index ≥28 kg\u002Fm² and \\\u003C40 kg\u002Fm².\n4. Willing to use effective contraception and have no pregnancy plan within 12 months after signing the informed consent form; female participants must have a negative pregnancy test at screening.\n5. Able to communicate with the investigators, willing to comply with the study protocol, and voluntarily sign the informed consent form.\n\nExclusion Criteria:\n\n1. Type 1 diabetes mellitus, type 2 diabetes requiring insulin treatment, or other specific types of diabetes.\n2. Body weight change \\>5% within 12 weeks before screening.\n3. Pregnant or breastfeeding women.\n4. Severe trauma, severe infection, or surgery within 1 month before screening that may affect glycemic control.\n5. Severe cardiovascular or cerebrovascular events within 6 months before screening, including angina, myocardial infarction, arrhythmia, cerebral infarction, cerebral hemorrhage, or other clinically significant events.\n6. History of acute or chronic pancreatitis, history of pancreatic injury, or amylase \\>1.5 × upper limit of normal at screening.\n7. Current or previous malignancy, except local basal cell carcinoma of the skin, carcinoma in situ of the cervix, or carcinoma in situ of the prostate; diagnosis of malignancy within 5 years before screening.\n8. Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2, or history of thyroid nodules.\n9. Blood dyscrasia or any disease causing hemolysis or unstable red blood cells, or hemoglobinopathy that may affect HbA1c measurement.\n10. History of organ transplantation or acquired or congenital immune system disease.\n11. Schizophrenia or other psychiatric disorder that may interfere with participation in the study.\n12. Unstable or treatment-requiring endocrine disease related to glycemic control, such as hyperthyroidism, acromegaly, or Cushing syndrome, as judged by the investigator.\n13. Hypertension with systolic blood pressure \\>150 mmHg and\u002For diastolic blood pressure \\>90 mmHg after stable antihypertensive treatment.\n14. Clinically significant abnormal gastric emptying, severe chronic gastrointestinal disease, diabetic gastroparesis, long-term use of medications directly affecting gastrointestinal motility, or history of gastrointestinal surgery.\n15. Special dietary requirements or allergy to foods such as soy products or dairy products.\n16. Use of medications affecting glucose regulation within 3 months before randomization, such as glucocorticoids, growth hormone, thyroid hormone, sex hormones, cyclosporine, or phenytoin.\n17. Allergic constitution, defined as allergy to two or more categories of substances.\n18. Fasting C-peptide \\\u003C0.81 ng\u002FmL.\n19. Calcitonin ≥50 pg\u002FmL.\n20. Abnormal laboratory results, including AST or ALT \\>2.5 × upper limit of normal, bilirubin \\>2.5 × upper limit of normal, triglycerides ≥5.7 mmol\u002FL, estimated creatinine clearance \\\u003C60 mL\u002Fmin using the Cockcroft-Gault formula, or clinically significant anemia with hemoglobin \\\u003C120 g\u002FL in men or \\\u003C110 g\u002FL in women.\n21. Unstable proliferative retinopathy or maculopathy requiring urgent treatment within 1 year before randomization, or history of diabetic ketoacidosis, hyperosmolar nonketotic coma, or severe metabolic disorder causing neuropsychiatric dysfunction.\n22. History or risk factors of epilepsy, syncope, cardiac arrest, arrhythmia, atrioventricular block, structural heart disease, torsades de pointes, hyperkalemia, hypokalemia, hypermagnesemia, hypomagnesemia, hypercalcemia, or hypocalcemia.\n23. Active bacterial, viral, or fungal infection requiring hospitalization or intravenous antibiotic treatment.\n24. Positive HBsAg, HCV antibody, HIV antibody, or Treponema pallidum antibody.\n25. Positive urine drug screening and\u002For drug dependence.\n26. Participation in another clinical trial within 3 months before enrollment or current participation in another drug or device clinical trial.\n27. Any other condition that, in the investigator's opinion, makes the participant unsuitable for this study.","ALL","18 Years","65 Years",{"count":21,"type":22},285,"ESTIMATED","INTERVENTIONAL",[25],"PHASE4","This multicenter randomized controlled trial will evaluate whether an AI-assisted intensive lifestyle intervention can improve weight and glycemic management in adults with obesity and newly diagnosed type 2 diabetes, compared with tirzepatide treatment and standard lifestyle management. Eligible participants will be adults aged 18 to 65 years with a body mass index of 28 to less than 40 kg\u002Fm² and newly diagnosed type 2 diabetes who have not used glucose-lowering medications in the past 3 months.\n\nParticipants will be randomly assigned to one of three groups: an AI-assisted intensive lifestyle intervention group, a tirzepatide treatment group, or a standard lifestyle management control group. The intervention period will last 52 weeks, followed by a 12-week post-intervention follow-up period. The main outcome is the percentage change in body weight at week 52. The study will also assess glycemic control, body composition, continuous glucose monitoring metrics, safety, and other metabolic outcomes.",[28,29],"Obesity","Diabetes Mellitus, Type 2",[31,32,33,34,35,36],"AI-Assisted Lifestyle Intervention","Tirzepatide","Weight Management","Glycemic Control","Continuous Glucose Monitoring","Randomized Controlled Trial","NOT_YET_RECRUITING","2026-07-10",{"date":40,"type":41},"2026-07-13","ACTUAL",{"date":43,"type":22},"2026-07-20",{"date":45,"type":22},"2028-01-31",{"name":47,"class":48},"The First Affiliated Hospital of Anhui Medical University","OTHER",2,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":17,"minAge":57,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":23,"phases":60,"briefSummary":62,"conditions":63,"keywords":65,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},"100636993","the-efficacy-and-safety-of-temporal-interference-stimulation-on-motor-symptoms-of-parkinsons-disease-100636993","NCT07572903","The Efficacy and Safety of Temporal Interference Stimulation on Motor Symptoms of Parkinson's Disease","The Efficacy and Safety of Temporal Interference Stimulation on Motor Symptoms of Parkinson's Disease: A Three-arm, Randomized, Double-blind, Parallel-controlled Study","Inclusion Criteria:\n\n1. Age \\>= 40 years;\n2. Meet the diagnostic criteria for primary Parkinson's disease (MDS Parkinson's Disease Diagnostic Criteria (2015 Edition));\n3. No medication adjustment in the 4 weeks before and during each stimulation;\n4. MDS-UPDRS III score \\>= 8 points, Hoehn-Yahr score 1-4 points\n\nExclusion Criteria:\n\n1. Focal brain injury or severe leukoencephalopathy (Fazekas grade 3 or above) on previous head MRI\u002FCT scans;\n2. Various secondary Parkinson's syndromes (vascular Parkinson's syndrome, drug-induced Parkinson's syndrome, etc.);\n3. Severe craniocerebral trauma, cranial surgery or deep brain stimulation treatment;\n4. Ferromagnetic implants in the body, such as cochlear implants, cardiac pacemakers, etc.;\n5. A history of epilepsy, unexplained loss of consciousness, or taking anticonvulsant drugs for epileptic seizures;\n6. Diagnosed with neuropsychiatric diseases other than Parkinson's disease;\n7. A history of drug abuse or drug use;\n8. Participated in any clinical trial in the past 3 months;\n9. Pregnant\u002Flactating women or subjects (including men) who plan to have children within 6 months;\n10. Other situations that the researchers consider unsuitable for inclusion.","40 Years",{"count":59,"type":22},90,[61],"NA","This study aimed to observe the clinical efficacy and safety of single-target transcranial temporal stimulation (tTIS) intervention in Parkinson's disease (PD) patients and explore the neurophysiological mechanism of TIS intervention. The study was designed as a three-arm (A: GPi group, B: STN group, C: Sham group), randomized, double-blind, parallel-controlled trial. PD patients in the drug-off state (≥12 hours after drug withdrawal) were randomly assigned to receive either tTIS or sham stimulation targeting GPi\u002FSTN, with each stimulation lasting 30 minutes. Clinical symptom assessments were conducted before and after the intervention, and safety was monitored by researchers throughout the process.",[64],"Parkinson s Disease",[64,66],"Temporal Interference Stimulation","RECRUITING","2026-05-07",{"date":70,"type":41},"2026-05-12",{"date":72,"type":41},"2026-05-06",{"date":74,"type":22},"2026-08-01",{"name":47,"class":48},1,{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":83,"enrollmentInfo":84,"targetDuration":4,"studyType":23,"phases":86,"briefSummary":87,"conditions":88,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":76},"100619573","clinical-study-on-the-safety-and-efficacy-of-temporal-interference-stimulation-in-the-treatment-of-post-stroke-aphasia-100619573","NCT07346378","Clinical Study on the Safety and Efficacy of Temporal Interference Stimulation in the Treatment of Post-Stroke Aphasia","Inclusion Criteria:\n\n* Diagnosed with post-stroke aphasia;\n* Right-handed;\n* Native Chinese speaker with comprehension of Mandarin;\n* Aged 18-80 years;\n* Complete relevant assessment and imaging data;\n* Informed consent obtained from the patient and their family.\n\nExclusion Criteria:\n\n* Cerebellar involvement in the stroke lesion, and incomplete scanning of cerebellar structures;\n* Severe dysarthria;\n* Concurrent epilepsy with occasional seizures;\n* Implanted pacemaker or deep brain stimulator;\n* History of brain tissue resection for prior lesions such as brain tumours or brain abscesses;\n* Other severe psychiatric disorders.","80 Years",{"count":85,"type":22},40,[61],"Neurological disorders encompass a wide variety of diseases, including congenital and neurodevelopmental disorders, cerebrovascular and neurodegenerative diseases, nervous system infections, neuroimmune diseases, neuromuscular or peripheral nervous system disorders, traumatic injuries, and tumor-related neurological conditions, with diverse symptomatic manifestations. The etiology, symptoms, and disease courses of these disorders vary significantly, severely impacting human health and social development, and have become a critical global public health issue. Some neurological disorders can lead to lifelong disability or high mortality rates, while others remain poorly understood, lacking effective treatments or cures.\n\nPost-stroke aphasia (PSA) is an acquired language impairment caused by ischemic or hemorrhagic injuries to the central nervous system. Its clinical manifestations are diverse, potentially affecting spontaneous speech, auditory comprehension, repetition, naming, reading, and writing abilities, among other aspects. Statistics indicate that over 16 million people worldwide suffer from stroke each year, with approximately 38% of survivors experiencing aphasia. The prognosis for this condition is concerning, as more than 40% of patients still exhibit significant language impairments one year after the stroke, with some even facing lifelong effects. The large patient population, significant communication barriers, and poor prognosis severely diminish patients' quality of life, significantly increasing their risk of emotional disorders such as depression and social isolation. This poses a substantial challenge to family caregiving and public health systems. Therefore, the development of non-invasive and effective novel therapeutic approaches holds substantial scientific and societal importance.\n\nTemporal interference stimulation (TI) technology represents a breakthrough in achieving non-invasive deep brain stimulation. This technology is based on the interference phenomenon, utilizing two pairs of surface electrodes to simultaneously apply sinusoidal wave stimuli at 2 kHz and 2.01 kHz. Two cortical regions are exposed to electric fields of 2 kHz or 2.01 kHz, and an interference electric field is generated in the brain region where these two fields overlap, with its envelope oscillating at 10 Hz. This technology has already been applied in the treatment of conditions such as depression, Parkinson's disease, and disorders of consciousness. The primary objective of this study is to explore the effects of TI intervention on deep brain regions, particularly on motor and non-motor related brain networks and functions in patients with neurological disorders, especially post-stroke aphasia. This research aims to provide a potential new approach for improving the clinical symptoms of these patients.",[89],"Post-stroke Aphasia","2026-03-20",{"date":92,"type":41},"2026-03-24",{"date":94,"type":41},"2025-12-01",{"date":96,"type":22},"2027-12-31",{"name":47,"class":48},{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":4,"eligibilityCriteria":104,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":105,"enrollmentInfo":106,"targetDuration":4,"studyType":23,"phases":108,"briefSummary":109,"conditions":110,"keywords":114,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":122,"leadSponsor":124,"locationsCount":4},"100613999","real-time-feedback-of-red-out-within-colonoscopy-intubation-100613999","NCT07273890","Real-time Feedback of Red-out Within Colonoscopy Intubation","Prospective, Multicenter, Controlled Study on the Impact of Real-time Feedback on Red-out","Inclusion Criteria:\n\n1. Study Participants (Patients):\n\n   Aged 18 to 70 years, any gender. Individuals scheduled to undergo diagnostic or screening colonoscopy at the investigational site.\n2. Colonoscopists:\n\nExpert-level colonoscopists (having performed a total of \\>1000 colonoscopy procedures).\n\nRight-handed.\n\nExclusion Criteria:\n\n1. Study Participants (Patients):\n\n   Individuals undergoing the following procedures:\n\n   cases with a history of colorectal surgery; cases with a history of chemotherapy, raditherapy; cases with a history of abdominal, and\u002For pelvic surgery; cases with a history of difficult colonoscopies; cases with colorectal tumours and obstructive lesions; cases with colorectal diverticula; cases with ulcerative colitis or Crohn's disease; cases with ischemic bowel disease; cases with colorectal polyposis; cases with melanosis coli; cases undergoing sigmoidoscopy; cases with poor intestional cleanliness (segment Boston bowel preparation scale (BBPS) of \\\u003C 2 points, total BBPS of \\\u003C 6 points); cases undergoing therapy procedures such as biopsy or CSP during the intubation phase; cases with transparent cap assisted colonoscopy; cases with water-assisted colonoscopy; cases with air insufflation level of M or L; cases failed caecal intubation within 15 min; cases with colonoscope stiffness level \\> 0; obese cases or underweight cases; and cases refusing participation.\n\n   Individuals who decline to provide informed consent.\n2. Colonoscopists:\n\nThose who have performed fewer than 300 complete colonoscopies in any calendar year within the past three years.\n\nThose who decline to participate in the study.","70 Years",{"count":107,"type":22},576,[61],"This study will employ a prospective, multicenter, controlled design. It will be conducted across multiple centers, with participated centers randomly assigned to one of four groups: Group A, Group B, Group C, and Group D.\n\nThe research will primarily focus on the AI-based analysis of colonoscopic images to calculate the following metrics: caecal intubation time, red-out percentage, and the AI-based red-out avoiding score. Based on the study's implementation protocol, a decision will be made regarding whether to provide real-time feedback. Additionally, the presence of any complications will be assessed both during and after the colonoscopy procedure.",[111,112,113],"Artificial Intelligence","Colonoscopy","Real-time Feedback",[112,115,116,117],"Intubation","Real-time feedback","Red-out","2025-11-27",{"date":120,"type":41},"2025-12-10",{"date":120,"type":22},{"date":123,"type":22},"2028-04-20",{"name":47,"class":48},{"id":126,"slug":127,"hasResults":11,"nctId":128,"briefTitle":129,"officialTitle":130,"acronym":4,"eligibilityCriteria":131,"healthyVolunteers":132,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":133,"targetDuration":4,"studyType":23,"phases":135,"briefSummary":136,"conditions":137,"keywords":139,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":147,"leadSponsor":149,"locationsCount":76},"100611984","phase-4-dose-escalation-of-rectal-indomethacin-for-preventing-pep-100611984","NCT07247682","Dose-escalation of Rectal Indomethacin for Preventing PEP","Dose-escalation of Rectal Indomethacin for Post-ERCP Pancreatitis Prevention in High-risk Patients: Protocol of a Multicentre Randomised Clinical Trial","Inclusion Criteria:Participants will be eligible for enrollment if they meet all of the following criteria: 1. age over 18 years; 2. classified as high risk for post-ERCP pancreatitis; 3. provision of signed, written informed consent.\n\nExclusion Criteria:Participants will be excluded if they meet any of the following conditions: 1. inaccessible major papilla; 2. surgically altered gastrointestinal anatomy; 3. current diagnosis of acute pancreatitis; 4. placement of a pancreatic stent; 5. contraindications to nonsteroidal anti-inflammatory drugs (NSAIDs), including known allergy, renal insufficiency, or active peptic ulcer disease; 6. anticipated low risk of post-ERCP pancreatitis (e.g., patients with chronic calcific pancreatitis, pancreatic head mass, or those undergoing biliary interventions through a pre-existing sphincterotomy); 7.severe active cardiopulmonary disease; 8. pregnancy or breastfeeding; 9. presence of an ampullary tumor.\n\n\\-",true,{"count":134,"type":22},1036,[25],"Our aim is to compare the efficacy of 100 mg versus 200 mg rectal indometacin in preventing post-ERCP pancreatitis (PEP) among high-risk patients without no pancreatic stenting. The 100 mg versus 200 mg indometacin trial is a multicentre, single-blind, randomized controlled study. High-risk patients for PEP without pancreatic stent insertion will be informed about the opportunity to participate. A total of 1,036 eligible patients will be randomly assigned in a 1:1 ratio to one of two groups: (1) administration of 100 mg rectal indometacin immediately after ERCP (standard-dose group), or (2) administration of 200 mg rectal indometacin immediately after ERCP (high-dose group). The primary outcome is the incidence and severity of PEP. Secondary outcomes include hyperamylasemia and other ERCP-related adverse events (AEs).",[138],"Post-ERCP Pancreatitis",[140,141,142],"post-ERCP pancreatitis","indometacin","ERCP","2025-11-18",{"date":145,"type":41},"2025-11-25",{"date":94,"type":22},{"date":148,"type":22},"2028-12-30",{"name":47,"class":48},{"id":151,"slug":152,"hasResults":11,"nctId":153,"briefTitle":154,"officialTitle":154,"acronym":155,"eligibilityCriteria":156,"healthyVolunteers":11,"sex":17,"minAge":157,"maxAge":158,"enrollmentInfo":159,"targetDuration":4,"studyType":23,"phases":161,"briefSummary":162,"conditions":163,"keywords":165,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":172,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":178,"locationsCount":4},"100607865","phase-4-remiazolam-vs-propofol-total-intravenous-anesthesia-on-postoperative-neurodevelopment-after-general-anesthesia-in-children-100607865","NCT07194109","Remiazolam vs Propofol Total Intravenous Anesthesia on Postoperative Neurodevelopment After General Anesthesia in Children","REMPPON","Inclusion Criteria:\n\n1. Age: 3-6 years old;\n2. Planned to undergo elective non-neurological, non-cardiac, and non-liver surgery under general anesthesia (abdominal surgery, orthopedic surgery, urological surgery, otolaryngological surgery, etc.);\n3. Expected anesthesia duration to be more than 30 minutes;\n4. ASA classification I-II;\n5. BMI 14-25 kg\u002Fm2;\n6. Postoperative plan not to be admitted to ICU;\n7. Parents or legal guardians of the child have given informed consent;\n8. Capable of communicating in Chinese.\n\nExclusion Criteria:\n\n1. Those who were exposed to general anesthetic drugs during infancy or in the late pregnancy of the mother;\n2. Known chromosomal abnormalities or other known acquired or congenital diseases that may affect neural development, such as cerebral palsy, autism spectrum disorder or attention deficit hyperactivity disorder (ADHD), etc.;\n3. Patients with severe liver dysfunction (Child-Pugh C grade);\n4. Patients with severe kidney dysfunction (requiring dialysis before surgery);\n5. Patients with a history of congenital heart disease requiring surgery or drug treatment;\n6. Those allergic to the study drugs remimazolam or propofol;\n7. Any known neural damage, such as cystic periventricular leukomalacia or grade 3 or 4 intraventricular hemorrhage;\n8. Social or geographical factors that may lead to postoperative loss of follow-up;\n9. Planned to undergo two surgeries within 7 days after the surgery;\n10. Those currently participating in other clinical trials;\n11. Those receiving special care or living in social welfare institutions or any other factors that may affect their ability to participate in the study.","3 Years","6 Years",{"count":160,"type":22},558,[25],"The goal of this clinical trial is to learn the effects of remimazolam for total intravenous anesthesia on the neurodevelopment of children aged 3-6 years who underwent tonsil\u002Fadenoid removal surgery after general anesthesia when compared with propofol. It will also learn about the safety of remimazolam used for children. The main questions it aims to answer are:\n\n* Does remimazolam improve the postoperative neurodevelopmental outcomes of the children after general anesthesia compared with propofol?\n* What medical problems do participants have when receive remimazolam for general anesthesia? Researchers will compare remimazolam to propofol to see if remimazolam improve the postoperative neurodevelopmental outcomes of the children after general anesthesia.\n\nParticipants will:\n\n* Receive remimazolam or propofol for general anesthesia induction and maintenance\n* At 1-3 years after the surgery, the Wechsler Preschool and Primary Scale of Intelligence - Fourth Edition was used for face-to-face assessment of the children's neurodevelopmental status.\n* Use scales such as BRIEF-P and CBCL to conduct face-to-face assessments of the patient's cognitive functions in other areas.",[164],"Adenotonsillar Hypertrophy",[166,167,168,169,170],"remimazolam","neurodevelopment","propofol","children","tonsillectomy","2025-09-25",{"date":173,"type":41},"2025-09-26",{"date":175,"type":22},"2025-10-01",{"date":177,"type":22},"2030-10-01",{"name":47,"class":48},{"id":180,"slug":181,"hasResults":11,"nctId":182,"briefTitle":183,"officialTitle":184,"acronym":185,"eligibilityCriteria":186,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":187,"targetDuration":4,"studyType":23,"phases":189,"briefSummary":190,"conditions":191,"keywords":194,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":200,"startDateStruct":202,"completionDateStruct":204,"leadSponsor":206,"locationsCount":76},"100599576","evaluation-of-the-efficacy-of-rhbnp-in-patients-with-diuretic-resistance-after-cardiac-surgery-100599576","NCT07086287","Evaluation of the Efficacy of rhBNP in Patients With Diuretic Resistance After Cardiac Surgery","Evaluation of the Efficacy of Recombinant Human Brain Natriuretic Peptide in Patients With Diuretic Resistance After Cardiac Surgery: a Prospective Single-center Single-blind Randomized Controlled Study","rhBNP","Inclusion Criteria:\n\n* (1) Adult patients after cardiac surgery (age ≥ 18 years) (2) Fluid overload (3) Diuretic resistance Definition: Daily intravenous use of furosemide at a dose ≥ 80mg or equivalent doses of other diuretics, yet still unable to achieve an adequate urine output of 0.5\\~1.0mL\u002Fkg\u002Fh. Conversion formula for different loop diuretics: Oral furosemide 80mg = Intravenous furosemide 40mg = Oral\u002FIntravenous torsemide 20mg = Oral\u002FIntravenous bumetanide 1mg (4) Willing to participate in the trial and sign the informed consent form.\n\nExclusion Criteria:\n\n* (1) Preoperative CKD patients undergo regular dialysis treatment; (2) Postoperative use of CRRT; (3) Drug allergies involved in this study; (4) Those with corrected systolic blood pressure still \\\u003C 90 mmHg after vasopressor use.",{"count":188,"type":22},120,[61],"evaluation of the efficacy of recombinant human brain natriuretic peptide in patients with diuretic resistance after cardiac surgery: a prospective single-center single-blind randomized controlled study",[192,193],"After Cardiac Surgery","Diuretic Resistance",[195,196,197,198],"recombinant human brain natriuretic peptide","diuretic resistance","after cardiac surgery","the incidence of renal replacement therapy","2025-07-18",{"date":201,"type":41},"2025-07-25",{"date":203,"type":22},"2025-08-01",{"date":205,"type":22},"2028-06-30",{"name":47,"class":48},{"id":208,"slug":209,"hasResults":11,"nctId":210,"briefTitle":211,"officialTitle":212,"acronym":4,"eligibilityCriteria":213,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":214,"targetDuration":4,"studyType":216,"phases":4,"briefSummary":217,"conditions":218,"keywords":222,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":225,"lastUpdatePostDateStruct":226,"startDateStruct":228,"completionDateStruct":230,"leadSponsor":232,"locationsCount":76},"100596830","lymph-node-metastasis-in-early-esophageal-squamous-cell-carcinoma-100596830","NCT07050576","Lymph Node Metastasis in Early Esophageal Squamous Cell Carcinoma","Deep Learning and Radiomics for Prediction of Lymph Node Metastasis in Early-stage Esophageal Squamous Cell Carcinoma","Inclusion Criteria:\n\n* Patients with pathologically confirmed early-stage (T1) ESCC\n* Preoperative contrast-enhanced CT data within 2 weeks before surgery\n* Without any treatment before surgical resection\n\nExclusion Criteria:\n\n* Patients who underwent neoadjuvant therapy or endoscopic treatment\n* Insufficient CT imaging or poor CT quality\n* Incomplete pathology results\n* Presence of metastatic disease",{"count":215,"type":22},500,"OBSERVATIONAL","This study aims to develop a predictive model using deep learning and radiomics to assess the likelihood of lymph node metastasis in patients with early-stage esophageal squamous cell carcinoma (ESCC). Lymph node metastasis is a critical factor in determining the treatment approach and prognosis for ESCC patients. By analyzing medical imaging data, we hope to create a non-invasive method that can assist doctors in making more accurate treatment decisions. This research could improve patient outcomes by enabling earlier and more tailored interventions.",[219,220,221],"ESCC","Lymph Node Metastasis","Radiomics",[219,223,224],"Lymph node metastasis","radiomics","2025-06-26",{"date":227,"type":41},"2025-07-03",{"date":229,"type":41},"2024-05-01",{"date":231,"type":22},"2025-11-30",{"name":47,"class":48},{"id":234,"slug":235,"hasResults":11,"nctId":236,"briefTitle":237,"officialTitle":238,"acronym":239,"eligibilityCriteria":240,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":241,"targetDuration":4,"studyType":23,"phases":243,"briefSummary":244,"conditions":245,"keywords":247,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":249,"lastUpdatePostDateStruct":250,"startDateStruct":252,"completionDateStruct":254,"leadSponsor":256,"locationsCount":49},"100535359","early-pancreatic-stent-placement-for-preventing-pep-100535359","NCT06250803","Early Pancreatic Stent Placement for Preventing PEP","Early Versus Late Pancreatic Stent Placement for Preventing Post-ERCP Pancreatitis: a Multicentre, Randomised Trial","EVL","Inclusion Criteria:\n\nParticipants who fulfill all the below criteria will be enrolled: 1. with naive papilla; 2. over 18 years; 3. undergoing ERCP with pancreatic guidewire-assisted technique for biliary access; 4. providing a signed, written informed consent.\n\nExclusion Criteria:\n\nParticipants who meet any of the following criteria will be excluded: 1. unreachable main papillae; 2. surgically altered gastrointestinal anatomy; 3. concurrent acute pancreatitis; 4. biliary cannulation over pancreatic duct stent after precut sphincterotomy or wire-guided method (native early attribute); 5. failed biliary cannulation; 6. severe active cardiopulmonary disease; 7. breastfeeding or pregnancy; 8. ampullary tumour.",{"count":242,"type":22},768,[61],"Our aim is to compare early versus late pancreatic stent placement in preventing PEP among patients with naive papilla. The EVL trial will provide essential answers regarding the optimal timing of prophylactic pancreatic stent placement in PEP prevention.All patients with difficult biliary cannulation undergoing endoscopic retrograde cholangiopancreatography (ERCP) with pancreatic guidewire-assisted technique for biliary access will be told about the opportunity to participate in EVL research. In total, 768 patients will be randomly assigned (1:1) to two arms: (1) early pancreatic stent placement (EPSP) (a pancreatic stent will be placed immediately after endoscopic retrograde cholangiography (ERC) or endoscopic sphincterotomy (EST)) and (2) late pancreatic stent placement (LPSP) (a pancreatic stent will be placed after all completion of therapeutic biliary procedures, e.g. biliary stone removal or drainage).The primary outcome is the rate and severity of PEP. The secondary outcomes are hyperamylasemia, the rate of stenting success, and other ERCP-related adverse events (AEs).",[246,138],"Cholangiopancreatography, Endoscopic Rretrograde",[246,248,140],"pancreatic stent","2025-03-12",{"date":251,"type":41},"2025-03-13",{"date":253,"type":41},"2024-04-01",{"date":255,"type":22},"2026-03-01",{"name":47,"class":48},{"id":258,"slug":259,"hasResults":11,"nctId":260,"briefTitle":261,"officialTitle":261,"acronym":4,"eligibilityCriteria":262,"healthyVolunteers":11,"sex":17,"minAge":263,"maxAge":4,"enrollmentInfo":264,"targetDuration":4,"studyType":216,"phases":4,"briefSummary":266,"conditions":267,"keywords":269,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":276,"lastUpdatePostDateStruct":277,"startDateStruct":279,"completionDateStruct":281,"leadSponsor":283,"locationsCount":76},"100559559","clinical-trial-on-the-accuracy-of-blood-pressure-measurement-by-ye990-medical-automatic-electronic-sphygmomanometer-100559559","NCT06565702","Clinical Trial on the Accuracy of Blood Pressure Measurement by YE990 Medical Automatic Electronic Sphygmomanometer","Inclusion Criteria:\n\nSubjects should meet all of the following requirements for inclusion in the study:\n\n1. Both sexes; at least 30% of the subjects are male and at least 30% of the subjects are female.\n2. Subject's age \\> 12 years.\n3. Arm circumference distribution:\n\n   1. At least 20% of the subjects should have arm circumference within each quarter interval of the total arm circumference range;\n   2. At least 10% of the subjects should have arm circumference within the upper one-eighth interval of the total arm circumference range;\n   3. At least 10% of the subjects shall have an arm circumference within the lower one-eighth interval of the total arm circumference range.\n4. Blood pressure distribution:\n\n   1. At least 5% of subjects shall have a systolic blood pressure ≤100 mmHg (13.33 kPa);\n   2. At least 5% of subjects shall have a systolic blood pressure ≥ 160 mmHg (21.33 kPa);\n   3. At least 20% of subjects should have a systolic blood pressure ≥ 140 mmHg (18.66 kPa);\n   4. Diastolic blood pressure should be ≤60 mmHg (8.0 kPa) in at least 5% of subjects;\n   5. Diastolic blood pressure should be ≥100 mmHg (13.33 kPa) in at least 5% of subjects; (f) At least 20% of subjects should have a diastolic blood pressure ≥85 mmHg (11.33 kPa);\n5. Subjects must be willing and able to comply with the study procedures by signing an informed consent form after being informed about the study.\n\n   consent form after understanding the contents of the study.\n6. Good compliance and ability to complete the clinical trial.\n\nExclusion Criteria:\n\nSubjects who fulfill any of the following requirements cannot be included in the study:\n\n(1) Mental illness, impaired consciousness, or other conditions that prevent them from cooperating with the study; (2) Require hemodialysis; (3) Taking anticoagulant drugs for cardiovascular diseases; (4) Pregnant and lactating women; (5) Patients with cardiac arrhythmia; (6) Patients with peripheral arterial disease and diseases that may affect arterial compliance; (7) Other conditions that are considered by the physician to be unsuitable for enrollment.\n\n\\-","12 Years",{"count":265,"type":22},85,"This study was a single-center, open-ended, self-controlled clinical study . Same armsequential method was used to measure the blood pressure of the subjects，inclusion of ≥85 subjects aged 12 years or older who met the enrollment criteria.In accordance with the \"Association for the Advancement of Medical Instrumentation\u002FEuropean Society of Hypertension\u002FInternational Organization for Standardization (AAMI\u002FESH\u002FISO) Universal Standard (ISO 81060-2:2018\u002FAmd 1:2020)\",the purpose of this study was to compare the blood pressure and pulse rate measured by an electronic sphygmomanometer with those measured by a reference sphygmomanometer (an upper-arm noninvasive auscultatory sphygmomanometer) and by palpation of the radial artery, and then to evaluate the accuracy and safety of the measurement of systolic blood pressure, diastolic blood pressure, and pulse rate by a fully automated electronic sphygmomanometer for medical use (Model No. YE990), which is manufactured by Jiangsu Yuyue Medical Equipment Co.",[268],"Blood Pressure",[270,271,272,273,274,275],"accuracy","systolic blood pressure","diastolic blood pressure","pulse rate","12 years of age or older","automatic electronic sphygmomanometers","2024-08-21",{"date":278,"type":41},"2024-08-22",{"date":280,"type":22},"2024-08-20",{"date":282,"type":22},"2025-12-30",{"name":47,"class":48},""]